tirzepatide or semaglutide Troubling Findings in Study of GLP-1 Compounders Many pharmaceutical industry experts had

International Journal of Pharmaceutical Compounding

Endocrinology 148 , 45334535 (2007)

Ce dernier bnfice demande nanmoins un approfondissement scientifique et clinique

European Journal of Endocrinology, [online] 191(1), pp.R22R31

[64], which involved a co-culture of primary astrocytes with the bEnd.3 endothelial cell line, incubation with exendin-4 reduced the levels of the astrocyte-derived vascular endothelial growth factor (VEGF-A), matrix metalloproteinase-9 (MMP-9), chemokine monocyte chemoattractant protein-1 (MCP-1), and the chemokine C-X-C motif ligand 1 (CXCL-1), induced by oxygenglucose deprivation (OGD), and subsequently led to the increased expression of tight junction proteins in the bEnd.3 cells

The oral form of tirzepatide is also in development, but it is a separate product from orforglipron